Siltuximab vs placebo or usual care
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
Siltuximab may leads to higher WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.97 [1.07, 3.63]1 study · 148 participantsLow